💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Bristol-Myers and Enterome team up to discover microbiome-based therapeutics in cancer

Published 11/16/2016, 07:18 AM
Bristol-Myers and Enterome team up to discover microbiome-based therapeutics in cancer
BMY
-
  • Bristol-Myers Squibb (NYSE:BMY) and Paris, France-based Enterome SA ink a collaboration agreement to discover and develop microbiome-derived biomarkers, drug targets and bioactive molecules as potential companion diagnostics and therapeutics for cancer. The partnership will also attempt to identify microbiome-derived biomarkers to improve clinical outcomes for patients treated with BMY's immuno-oncology products.
  • The collaboration will leverage BMY's know-how in the discovery and development of immunotherapies with Enterome's proprietary metagenomic technology platform and leadership in the science of the gut microbiome.
  • Under the terms of the deal, Enterome will receive an upfront payment of $15M for R&D funding and access to its technology, milestones for each licensed therapeutic candidate and royalties on net sales. It is also eligible for milestones related to new diagnostic products. BMY will have exclusive rights to the intellectual property and therapeutics generated under the collaboration.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.